

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO DECLARE
FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part 1	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
B (I)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>
D	<input checked="" type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>
G	<input checked="" type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: ___ 04 March 2010 _____

State Party to the Convention: _____ AUSTRIA _____

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility² Federal Ministry of Defence
Armament and Defence Technology Agency
NBC & Environmental Protection Technology
Division
2. Responsible public or private organization or company Government (MoD) _____
3. Location and postal address Laboratory Location:
Robert Koch-Gasse 17, A-2340 MÖDLING
Head Office:
Roßauer Lände 1, A1090 VIENNA
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Government (MoD)
5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)
0 _____
6. If no maximum containment unit, indicate highest level of protection
BSL 3 _____
7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Providing Expertise and analytical capacity for the Federal Ministry of Defence for Improvement of B-Defence capabilities.
Sampling and detection of potential B-warfare and bioterrorism agents.
Evaluation of sampling and detection procedures.
Agents: e.g. *Bacillus* sp., *Yersinia* sp., *Brucella* sp., *Coxiella*, *Francisella* sp., *Burkholderia* sp., *Vibrio* sp., Yellow Fever, VEE, Vaccinia, Ricin.

¹ The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

² For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³ In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/~~No~~

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Diagnostic techniques:	molecular (e.g. PCR, Real-Time PCR sequencing), immunological (e.g. ELISA)
Detection :	development and evaluation of test procedures
Decontamination:	evaluation of efficiency of B-decontamination products & procedures
Sampling:	Evaluation of sampling procedures

2. State the total funding for the programme and its source.

Source of funding: MoD

Total funding 2009 approximately: Euro 27 000,-

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

MoD-laboratory physically located at a governmental non-defence facility but organizationally separated from this institution.

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Federal Ministry of Defence
Armament and Defence Technology Agency
Div NBC & Environmental Protection Technology
2. Where is it located (include both address and geographical location)?
Robert Koch-Gasse 17, A-2340 Mödling (approx. 15 km south of Vienna)
3. Floor area of laboratory areas by containment level:
BL2 _____38_____ (sqM)
BL3 _____45_____ (sqM)
BL4 _____0_____ (sqM)
Total laboratory floor area _____83_____ (sqM)
4. The organizational structure of each facility.
 - (i) Total number of personnel _____2 (MoD)_____
 - (ii) Division of personnel:
Military _____0_____

Civilian _____2_____
- (iii) Division of personnel by category:
Scientists _____2_____

Engineers _____0_____
Technicians _____0_____
Administration and support staff _____general support_____

- (iv) List the scientific disciplines represented in the scientific/engineering staff.

Molecular Biology
Biochemistry/Microbiology

- (v) Are contractor staff working in the facility? If so, provide an approximate number.

- (vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence and Sports?

100% government (MoD)

- (vii) What are the funding levels for the following programme areas:

Research	<u>approx. 45%</u>
Development	<u>approx. 15%</u>
Test and evaluation	<u>approx. 40%</u>

- (viii) Briefly describe the publication policy of the facility:

Currently no publication activity

- (ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

See form A, part 1/7; no outdoor studies of biological aerosols

*Including viruses and prions.

**Background information on outbreaks of reportable
infectious diseases**

Disease	Number of cases per year				
	1988	1989	1990	1991	1992

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

1. Time of cognizance of the outbreak
2. Location and approximate area affected
3. Type of disease/intoxication
4. Suspected source of disease/
intoxication
5. Possible causative agent(s)
6. Main characteristics of systems
7. Detailed symptoms, when applicable
 - respiratory
 - circulatory
 - neurological/behavioural
 - intestinal
 - dermatological
 - nephrological
 - other
8. Deviation(s) from the normal pattern as regards
 - type
 - development
 - place of occurrence
 - time of occurrence
 - symptoms
 - virulence pattern

- drug resistance pattern
 - agent(s) difficult to diagnose
 - presence of unusual vectors
 - other
9. Approximate number of primary cases
 10. Approximate number of total cases
 11. Number of deaths
 12. Development of the outbreak
 13. Measures taken

4. CONFIDENCE-BUILDING MEASURE "C":

- **Encouragement of publication of results and promotion of use of knowledge**

At the Third Review Conference it was agreed that States parties continue to implement the following:

"Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research."

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, inter alia, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

For each such event, the following information should be provided:

- name of the conference, etc.
- arranging organization(s), etc.
- time
- place
- main subject(s) for the conference, etc.
.....
- conditions for participation
-
- point of contact for further
information, registration, etc.
.....
.....

2. Information regarding other opportunities

.....
.....
.....

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES/ NO	YES/ NO	YES/ NO	YES /NO
(b) Exports of micro-organisms* and toxins	YES/ NO	YES/ NO	YES/ NO	YES /NO
(c) Imports of micro-organisms* and toxins	YES/ NO	YES/ NO	YES/ NO	YES /NO

** Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.

10.8.1973

2. Past offensive biological research and development programmes:

- ~~YES~~ / NO

- Period(s) of activities

- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:

- ~~YES~~ / NO

- Period(s) of activities

- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Declaration of vaccine production facilities

1. Name of facility:
2. Location (mailing address):
3. General description of the types of diseases covered: